ERBB2 (HER2) protein expression in uterine sarcomas

被引：0
作者：
Zafrakas, M. [1 ]
Zepiridis, L. [1 ]
Theodoridis, T. D. [1 ]
Venizelos, I. D. [2 ]
Papanicolaou, A. [1 ]
Agorastos, T. [1 ]
Bontis, J. N. [1 ]
机构：
[1] Aristotle Univ Thessaloniki, Dept Obstet & Gynecol 1, Papageorgiou Gen Hosp, Thessaloniki 56403, Greece
[2] Hippokrateio Gen Hosp, Dept Pathol, Thessaloniki, Greece
来源：
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY | 2009年 / 30卷 / 03期
关键词：
Uterine sarcoma; ERBB2; HER2; Targeted therapy; Trastuzumab; Herceptin (R); Lapatinib; Tykerb (R); METASTATIC BREAST-CANCER; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; OF-THE-LITERATURE; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; TRASTUZUMAB; CARCINOSARCOMA; HER-2/NEU; THERAPY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: Multiple clinical trials in recent years have shown that breast cancer patients with primary tumors overexpressing ERBB2 can be effectively treated with specific forms of modern anti-ERBB2-targeted therapy. The aim of the present study was to analyze the expression of the ERBB2 (HER2) protein in uterine sarcomas, in order to investigate the possibility of applying this treatment modality in uterine sarcomas. Methods: The expression of ERBB2 has been analyzed immunohistochemical in formalin-fixed paraffin-embedded primary uterine sarcomas (n = 11). Results: Using a semi-quantitative immunohistochemical score, we found that ERBB2 expression was very weak in the majority of tumors, with only three sarcomas showing moderate ERBB2 expression. Published studies evaluating the same issue in small numbers of uterine sarcomas reached similar findings. Conclusion: Overall, ERBB2 expression appears to be weak in uterine sarcomas. However, targeted treatment might still be feasible in a subgroup of patients with uterine sarcomas overexpressing ERBB2.
引用
收藏
页码：292 / 294
页数：3
相关论文
共 50 条
  • [1] Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma
    Cenaj, Odise
    Ligon, Azra H.
    Hornick, Jason L.
    Sholl, Lynette M.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 152 (01) : 97 - 108
  • [2] Targeting HER2 in Colorectal Cancer: The Landscape of Amplification and Short Variant Mutations in ERBB2 and ERBB3
    Ross, Jeffrey S.
    Fakih, Marwan
    Ali, Siraj M.
    Elvin, Julia A.
    Schrock, Alexa B.
    Suh, James
    Vergilio, Jo-Anne
    Ramkissoon, Shakti
    Severson, Eric
    Daniel, Sugganth
    Fabrizio, David
    Frampton, Garrett
    Sun, James
    Miller, Vincent A.
    Stephens, Philip J.
    Gay, Laurie M.
    CANCER, 2018, 124 (07) : 1358 - 1373
  • [3] HER2/ERBB2 immunoreactivity in human retinoblastoma
    Seigel, G. M.
    Sharma, S.
    Hackam, A. S.
    Shah, Dhaval K.
    TUMOR BIOLOGY, 2016, 37 (05) : 6135 - 6142
  • [4] Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells
    Shibata, Tomohiro
    Kan, Hitoshi
    Murakami, Yuichi
    Ureshino, Hiroki
    Watari, Kosuke
    Kawahara, Akihiko
    Kage, Masayoshi
    Hattori, Satoshi
    Ono, Mayumi
    Kuwano, Michihiko
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05) : 737 - 746
  • [5] Treatment of patients with HER2 (erbB2) positive breast cancer. A classic example for the transfer of molecular information to the clinic
    Untch, M.
    Jackisch, C.
    ONKOLOGE, 2009, 15 (08): : 811 - 825
  • [6] Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
    Moutafi, Myrto
    Robbins, Charles J.
    Yaghoobi, Vesal
    Fernandez, Aileen, I
    Martinez-Morilla, Sandra
    Xirou, Vasiliki
    Bai, Yalai
    Song, Yan
    Gaule, Patricia
    Krueger, Joseph
    Bloom, Kenneth
    Hill, Salisha
    Liebler, Daniel C.
    Fulton, Regan
    Rimm, David L.
    LABORATORY INVESTIGATION, 2022, 102 (10) : 1101 - 1108
  • [7] HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
    Plum, Patrick Sven
    Gebauer, Florian
    Kraemer, Max
    Alakus, Hakan
    Berlth, Felix
    Chon, Seung-Hun
    Schiffmann, Lars
    Zander, Thomas
    Buettner, Reinhard
    Hoelscher, Arnulf Heinrich
    Bruns, Christiane Josephine
    Quaas, Alexander
    Loeser, Heike
    BMC CANCER, 2019, 19 (1)
  • [8] Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program
    Morey, Adrienne L.
    Brown, Belinda
    Farshid, Gelareh
    Fox, Stephen B.
    Francis, Glenn D.
    McCue, Glenda
    von Neumann-Cosel, Vita
    Bilous, Michael
    PATHOLOGY, 2016, 48 (06) : 535 - 542
  • [9] Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers
    Tomizawa, Kenji
    Suda, Kenichi
    Onozato, Ryoichi
    Kosaka, Takayuki
    Endoh, Hideki
    Sekido, Yoshitaka
    Shigematsu, Hisayuki
    Kuwano, Hiroyuki
    Yatabe, Yasushi
    Mitsudomi, Tetsuya
    LUNG CANCER, 2011, 74 (01) : 139 - 144
  • [10] Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers
    Zheng-Lin, Binbin
    Graham, Rondell P.
    Bekaii-Saab, Tanios S.
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (05)
12345